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Steroid response encephalopathy associated with autoimmune thyroiditis (SREAT), or Hashimoto’s encephalopathy, is a rare
disorder believed to be immune-mediated. It is most often characterized by a subacute onset of confusion with altered level of
consciousness, seizures, and myoclonus. We describe the case of a 48-year-old gentleman who presented with confusion and
dysphasia. Speciﬁc clinical features and laboratory results led to a diagnosis of Hashimoto’s encephalopathy. This case highlights
the core features of this condition and the potential for complete response to steroid therapy.
1.Introduction
Steroid response encephalopathy associated with autoim-
mune thyroiditis (SREAT) is a rare disorder ﬁrst described
in 1966. It can present acutely with multiple recurrent
focal neurological events or with a progressive, diﬀuse
pattern characterized by cognitive impairment. It is under-
recognized by physicians, and the purpose of this report is to
add to the literature and highlight the potential for excellent
clinical outcome with appropriate therapy.
2. Case Presentation
A 48-year-old gentleman presented to the emergency depart-
ment with a six-hour history of confusion and dysphasia. He
was a smoker of ﬁve cigars a day and consumed 40 units of
alcohol per week. His past medical history was notable for an
episode of pancreatitis. His son had type 1 diabetes mellitus;
family history was, otherwise, unremarkable.
His wife described two discrete episodes of bizarre
behaviour in the year prior to his current admission.
She reported behaviour such as shaking salt into his tea
and mixing up various household utensils. The ﬁrst of
these episodes lasted three days and was associated with
ataxia. The second, six months later, was associated with
an expressive dysphasia. Investigations at that time included
routinebloods,ANA,ANCA,CTbrain,MRIbrain,andEEG,
all of which were normal. A lumbar puncture during the
second episode yielded CSF with normal cytology but an
elevated protein of 1g. His work colleagues also reported
some intermittent unusual behaviour and subtle personality
changes in recent months. His clinical condition improved
spontaneously on both of these occasions and a presumptive
diagnosis of transient ischaemic attacks was made.
When reviewed in the emergency department on this
occasion, he was agitated. Vital signs were normal. He
had an expressive dysphasia and appeared disorientated
and confused scoring 26/30 on the minimental state score
(MMSE). Cranial and peripheral nerve examinations were
normal, as was fundoscopy. There was no meningism.
Cardiorespiratory and abdominal examinations were nor-
mal. Initial investigations revealed normal full blood count,
inﬂammatorymarkers,electrolytes,andrenalfunction.Liver
function tests, alpha-feto protein, and ammonia levels were
normal. CK was mildly elevated at 211. CT brain and MRI
brain using a 1.5 Tesla machine were normal. CSF analysis
revealed an elevated protein of 0.81 with normal cytology
andglucose.EEGrevealedintermixedthetaactivity.Overthe
following days, he developed myoclonus, a marked startle
reﬂex, diﬀuse rigidity, hyperreﬂexia, and a ﬁne tremor. He
also developed generalised seizures.
Further laboratory tests including VDRL, TPHA, ANCA,
anti-GBM, heavy metal screen, antineuronal antibodies, red
cell transketolase, brucella, mycoplasma, and lyme serology2 Case Reports in Medicine
were all normal. Autoimmune screen and haematinics
including vitamin B12 levels were likewise normal.
Thyroid function showed T4 10.3 and TSH 9.97 with
markedly elevated anti-thyroid peroxidase antibodies at
25600 and normal antithyroglobulin antibodies. A diag-
nosis of Hashimoto’s encephalopathy was made and high-
dose steroids initiated. Within days, there was marked
clinical improvement with full resolution of confusion and
myoclonus. He was discharged well several days later on
high-dose oral prednisolone. This was gradually reduced
over six months, without relapse. One year after this hospital
admission, routine thyroid function tests revealed overt
hypothyroidism with T4 of 7.4 and TSH of 51. At this point,
thyroxine replacement was introduced.
3. Discussion
Hashimoto’s encephalopathy remains a controversial entity
since its ﬁrst description in 1966 [1]. The exact aetiology has
yet to be elucidated although is assumed to be autoimmune.
Current opinion is divided on the exact nature of this
autoimmune response. Primary demyelination, vasculitis,
immune complex deposition, and direct antibody-mediated
neuronal injury have all been proposed as mechanisms of
disease. It is characterised by confusion with or without
myoclonus, seizures, hyperreﬂexia, and psychosis. Presenta-
tion may be an insidious development of cognitive impair-
ment or recurrent acute episodes of focal neurological deﬁcit
with confusion [2].
Laboratory ﬁndings are largely nonspeciﬁc. There is
typically a raised CSF protein level with normal glucose
with or without a lymphocytic pleocytosis. Nonspeciﬁc EEG
abnormalities usually comprising slowing of background
activityareseeninthemajorityofpatients,whilstfocalspikes
or sharp waves are less common [3]. There are reports of
EEG abnormalities recovering rapidly with steroid therapy
while other cases illustrate a lag between EEG improvement
and clinical improvement [4]. Magnetic resonance imaging
(MRI) may be normal or demonstrate nonspeciﬁc T2 signal
abnormalities in the subcortical white matter that do not
enhance with gadolinium. In rare cases, diﬀuse white matter
changes or meningeal enhancement have been described
[2]. Imaging using higher ﬁeld magnets such as 3T MR
scanners may detect subtle abnormalities not seen on the
1.5T machine used in our case. Thyroid dysfunction may be
present. The most striking abnormality is raised antithyroid
antibodies. Antithyroid peroxidase antibodies are markedly
elevated with or without elevated antithyroglobulin antibod-
ies [4].
Initial treatment is with high-dose steroids titrated
according to clinical response [5]. Thyroid dysfunction
should also be appropriately treated if present. Response to
steroid therapy is usually excellent and is followed by slow
steroid tapering and eventual discontinuation. Steroid intol-
erant patients may respond to cyclosporine or azathioprine.
There are also several case reports describing good clinical
outcomes following plasma exchange [6] and intravenous
immunoglobulin [7]. It is unclear whether this condition is
directly related to thyroid disease or whether the relationship
is due to diﬀerential expression of an autoimmune phe-
notype. The term steroid-responsive encephalopathy asso-
ciated with autoimmune thyroiditis (SREAT) is, therefore,
preferred by some authorities. The long-term neurological
prognosis in Hashimoto’s encephalopathy is good. Persistent
cognitive deﬁcits develop in a minority and are more likely if
treatment is considerably delayed [8].
There remains much to be discovered regarding the
pathogenesis of Hashimoto’s encephalopathy. It should be
considered in the diﬀerential diagnosis of any metabolic
encephalopathy as prompt treatment can lead to excellent
recovery.
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